Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 66 clinical trials
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of ICP-022 versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.

rituximab
chronic lymphocytic leukemia
chlorambucil
  • 1 views
  • 09 Apr, 2022
  • 24 locations
A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)

Ibrutinib, an inhibitor of Brutons tyrosine kinase (BTK) is approved in CLL as continuous, daily administration of 420 mg orally until progression. Ibrutinib drug costs in health care are rapidly increasing and are difficult to predict, as long-term follow up analyses have shown that many patients remain on therapy for …

  • 0 views
  • 05 Mar, 2021
  • 9 locations
Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer …

TP53
venetoclax
chronic lymphocytic leukemia
thrombocytopenia
monoclonal protein
  • 16 views
  • 22 Oct, 2022
  • 241 locations
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

This phase II trial investigates the how well acalabrutinib and obinutuzumab work in treating patients with chronic lymphocytic leukemia (CLL). Acalabrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab may induce changes in body's immune system and may …

lymphoma
lymphoid leukemia
chronic lymphocytic leukemia
acalabrutinib
gilbert's syndrome
  • 7 views
  • 04 Oct, 2022
  • 1 location
A Phase Ib/II Study of the Safety, Pharmacokinetic, Pharmacodynamic and Efficacy of APG-2575 Single Agent and in Combination With Other Therapeutic Agents in Patients With Relapsed/Refractory CLL/SLL

The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-2575 single agent and in combination with other therapeutic agents in patients with relapsed/refractory CLL/SLL.

ibrutinib
lymphoma
lymphoid leukemia
chronic lymphocytic leukemia
rituximab
  • 0 views
  • 10 Oct, 2022
  • 17 locations
An Open-label, Phase 1/2, First in Human Study Investigating the Safety, Tolerability, Pharmacokinetics and Efficacy of NVG-111 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma

This is the first clinical trial of the drug NVG-111, and will include patients with certain types of blood cancer called chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL). NVG-111 is a bispecific antibody drug, having two "arms", one arm attaches to a substance on …

lymphocytic leukemia
venetoclax
monoclonal protein
tyrosine
lymphoma
  • 0 views
  • 20 Oct, 2022
  • 1 location
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

This phase II trial tests whether acalabrutinib, venetoclax, and durvalumab work in treating patients with Richter transformation from chronic lymphocytic leukemia or small lymphocytic lymphoma. Richter transformation is a rare condition in which chronic lymphocytic leukemia or small lymphocytic lymphoma changes into a fast-growing type of lymphoma. Acalabrutinib may stop …

measurable disease
venetoclax
chronic lymphocytic leukemia
monoclonal protein
acalabrutinib
  • 0 views
  • 02 Jul, 2022
  • 1 location
A Study Of The Selective PKC-β Inhibitor MS- 553

A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

lymphoma
lymphoid leukemia
chronic lymphocytic leukemia
acalabrutinib
venetoclax
  • 14 views
  • 13 Jun, 2022
  • 5 locations
A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL

This is a Phase I/II, single arm, multi-center, open-label clinical trial of MS-553 in patients with CLL/SLL whose disease relapsed after or was refractory to at lease 1 prior therapy (chemotherapy and/or targeted drug therapy, which must include BTK inhibitor therapy) and who are indicated for treatment per IWCLL2018.

btk inhibitor
  • 0 views
  • 10 Jul, 2022
  • 1 location
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, …

lymphoid leukemia
chronic lymphocytic leukemia
acalabrutinib
monoclonal protein
immunoglobulin
  • 7 views
  • 07 Oct, 2022
  • 3 locations